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Intestine epithelial cell apoptosis
Akt
Inﬂammatory bowel diseaseA common feature of inﬂammatory bowel disease (IBD) is the loss of intestinal epithelial barrier function
due to excessive apoptosis of intestinal epithelial cells (IECs). However, the molecular mechanism
underlying increased IEC apoptosis remains unclear. Here, we investigated the role of PHLPP, a novel family
of protein phosphatases, in regulating inﬂammation-induced IEC apoptosis in mouse models of colitis. Both
Phlpp1 and Phlpp2 genes were deleted in mice. Compared with wild-type mice, PHLPP double knockout
(DKO) mice were protected from colitis induced by DSS as demonstrated by lower histopathological scores,
and this reduced susceptibility to colitis was associated with decreased apoptosis and increased Akt activity
in IECs in vivo. In addition, epithelial organoids derived from PHLPP DKO mice were more resistant
to inﬂammation-induced apoptosis while inhibition of Akt activity abolished the protective effect of
PHLPP-loss. Furthermore, we found that PHLPP expression was signiﬁcantly reduced in IECs following the
induction of colitis by DSS and in human IBD patient samples. This inﬂammation-induced downregulation
of PHLPPwas partially blocked by treating cells with a proteasome inhibitor. Taken together, our results indicated
that proteasome-mediated degradation of PHLPP at the onset of inﬂammation plays an important role in
protecting IEC injury by inhibiting apoptosis.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Inﬂammatory bowel disease (IBD) primarily includes ulcerative colitis
and Crohn's disease and is characterized by chronic or recurring inﬂam-
mation of the gastrointestinal tract [1–3]. Progressive inﬂammation
usually leads to irreversible damage to the gastrointestinal tract, and
patients with IBD are at increased risk for developing colorectal cancer
(CRC) [4,5]. Although the underlying cause of IBD is still largely unde-
ﬁned, it is well known that intestinal epithelial cells (IECs), by forming
a barrier to the luminal microbes, play a pivotal role in the pathogenesis
of IBD. Apoptosis of IECs is a tightly regulated process in normal intestinal
epithelium, and increased cell death has been detected at the inﬂamma-
tory site in both IBD patients andmousemodels of colitis [6–8]. However,
the molecular mechanism underlying increased IECs apoptosis during
intestinal inﬂammation remains unclear.knockout; IBD, inﬂammatory
nohistochemistry; PHLPP, PH
phosphoinositide 3-kinase; UC,
ar and Cellular Biochemistry,PHLPP (PH domain Leucine-rich-repeats Protein Phosphatase) be-
longs to a novel family of Ser/Thr protein phosphatases that play a critical
role in controlling the balance of cell death and proliferation [9–12].
There are two isoforms, PHLPP1 and PHLPP2, identiﬁed in this family
[9]. Previous studies have identiﬁed PHLPP as a protein phosphatase
and negative regulator of Akt [13,14]. It has been shown that PHLPP-
mediated dephosphorylation inactivates Akt and leads to increased apo-
ptosis [13,14]. Numerous studies have shown that increased Akt activity
suppresses apoptosis in both normal and cancer cells [15]. Interestingly,
activation of Akt downstream of phosphoinositide 3-kinase (PI3K) has
been shown to be required for inﬂammation-induced dysplasia in
mouse models of IBD [16]. Given the role of PHLPP in negatively regulat-
ing Akt signaling [13,14], it is of particular interest to determine the func-
tional importance of PHLPP in the pathogenesis of IBD. In this study, we
reported that genetic deletion of both PHLPP genes protects mice against
colitis by inhibiting IEC apoptosis and upregulating Akt activity. In addi-
tion, the expression of PHLPP is signiﬁcantly reduced inmouse IECs treat-
ed with DSS and in IBD patient samples. Our ﬁndings suggested that
downregulation of PHLPP provides the initial protection against
inﬂammation-induced cell death under colitis conditions. However, aber-
rant activation of Akt as a result of PHLPP-loss in IECs may contribute to
the pathological progression to colon cancer.
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2.1. Animals
All animal procedures were performed by following protocols
approved by the University of Kentucky Institutional Animal Care
and Use Committee. The Phlpp1 null mouse stain on 129 Sv/C57BL6
background was generated as recently described [12,17]. The Phlpp2
knockoutmouse linewas created using the Knockout-First (KF) strategy
[18,19], which allows both conventional and conditional knockout of
Phlpp2 gene. Mouse ES cells containing the Phlpp2 KF allele were
obtained from the EuropeanMouse Mutant Cell Repository (EuMMCR).
The Phlpp2 KF mouse strain was generated by using services provided
by the University of California Davis Mouse Biology Program. The
Phlpp2 knockout (Phlpp2–/−–) mice are mice carrying the KF cassette
which essentially ablates the expression of endogenous Phlpp2
gene. To produce animals used in this study, Phlpp1–/− were bred
with Phlpp2–/−– mice on C57BL6 background. These mice were
then inter-crossed to sustain aheterogeneousmixed genetic background.
The Phlpp1/2 DKOmicewere fertile and born at the expectedMendelian
ratio, and the normal physiological functionswere generally not affected.
Four cohorts of animals were produced, including wild-type (WT),
Phlpp1–/−–, Phlpp2−/−–, and Phlpp1/2 double knockout (DKO). The fol-
lowing PCRprimerswere used for genotyping: for Phlpp1, 5′-TAGGAGAG
ACTAGTGACATC-3′, 5′-TGAGCTTATACGCTGTGATGC-3′, and 5′-AGCCGA
TTGTCTGTTGTGC-3′; and for Phlpp2, 5′-GATGCTCTGCTTCTGCTCCTGT
GC-3′, 5′-GATATGAGGAACGAAGCAATATGGG-3′, and 5′-CAACGGGTTC
TTCTGTTAGTCC-3′. The schematic of Phlpp2 knockout allele and a
representative result of Phlpp2 genotyping are shown in Supplementary
Fig. S1.
2.2. Reagents and cells
The following chemicals, including PI3K inhibitor LY290042 and
proteasome inhibitor MG132, were purchased from EMD/CalBiochem.
TNFα was obtained from Peprotech and lipopolysaccharide (LPS) was
from Sigma-Aldrich. Human colon cancer Caco2 cells were cultured in
DMEM supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich)
and 1% penicillin/streptomycin.
2.3. Induction and assessment of colitis
TheWT and PHLPPDKOmice, 10 to 12week old including bothmale
and female littermates, were randomized to administered 2% DSS (MW
36, 000–50,000, MP Biomedicals) in the drinking water for 7 days. The
control groups were given regular drinking water. Daily changes in
bodyweight and clinical signs of colitis, such as rectal bleeding, diarrhea,
and bloody stool, were assessed and reported as a score from0 to 4. Fecal
Occult Blood Test (Sure-Vue, Fisher Healthcare, Houston, TX) was used
to test fecal blood in stool samples. The disease activity index was
determined based on weight loss, stool consistency, and bleeding, as
described previously by Murthy et al. [20]. WT and Phlpp knockout
mice used in the experiments were littermates that were raised in the
same animal facility and treated at the same time.
For histological assessment of colonic damage, colons were opened
longitudinally, ﬂushed with PBS, and ﬁxed in 10% buffered formalin.Fig. 1. Suppression of DSS-induced colitis in PHLPP-DKOmice. Colitis was induced inwild-type (W
The clinical progression of the colitis was determined by the percentage change in body weight (A
was normalized to that of before the treatment. DAI ofWT andDKOmicewas calculated as describ
7 females; and 13 animals for DKO group including 5males and 8 females. *, P b 0.0001WT vs.DK
equally resistant toDSS-induced colitis compared toWTmice. (C) Colon tissueswere collected from
(H&E) staining. Scale bar for images on the left= 500 μm; and for images on the right=200 μm. (
was scored based on H&E staining as shown in C. Data representmeans± SEM (n=5 animals/gr
DSS for 7 days. Data represent means ± SEM (n = 12 and 13 animals for WT and DKO groups,
inﬂammatory cell inﬁltrate in DSS-induced colitis of WT and DKO mice. Colon fromWT and DK
on the left = 200 μm; and for images on the right = 100 μm.The colons were Swiss-rolled to examine entire length of the colon and
processed in parafﬁn. Hematoxylin and eosin (H&E)-stained sections
were prepared from ﬁxed and parafﬁn embedded colon specimens by
following standard techniques. Histological scores of colitis were deter-
mined based on the previously described morphological criteria [21].
For assessing apoptosis, TUNEL staining was performed using the
In Situ Cell Death Detection Kit, Fluorescein (Roche Applied Science)
according to manufacturer's protocol. Tissue sections were counter-
stained with DAPI and analyzed using a Nikon TE2000 inverted
microscope. The number TUNEL-positive cells per 100 enterocytes
(termed apoptosis index) was quantiﬁed and analyzed using Nikon
Element AR software.2.4. Immunohistochemical (IHC) staining
For IHC staining, parafﬁn-embedded tissue sections were
deparafﬁnized, rehydrated, and treated with hydrogen peroxide.
Antigen retrieval was performed using Dako Target Retrieval Solution
(DakoCytomation), and IHC staining was performed as previously
described [12,22]. The stained sections were visualized using a Leica
DM750 microscope. The F4/80 antibody was purchased from Abcam
and the β-catenin antibody was obtained from Bethyl Laboratory.2.5. Culture of mouse intestine and colon organoids
Mouse intestine and colon crypt were isolated and cultured in 3D
Matrigel as described previously [23] with minor modiﬁcations. Brieﬂy,
fresh mouse intestine or colon tissues were incubated in cold digestion
buffer (2mMEDTA and 0.5 mMDTT in PBS) for 30min on ice, and then
incubated in TrypLE Express (Life Technologies) at 37 °C for 15 min.
After removing TrypLE Express, crypts were dislodged in cold PBS via
vigorous vortex, and the crypt suspension was passed through a cell
strainer (70 μm) to remove un-disassociated tissue materials. Isolated
crypts were collected after centrifugation at 200 g for 3 min and subse-
quently re-suspended in 100 μl of 50% Matrigel [Matrigel mixed 1:1
(v:v) with basal medium (DMEM/F12 supplemented with penicillin/
streptomycin, HEPES, 1× N2, 1× B27, and 1 mM N-Acetylcysteine)] and
seeded in eachwell of a 24-well plate. Once theMatrigel had set, organoid
medium was added, and the organoids were cultured for 4–7 days as
speciﬁed in the experiments. The organoid medium for mouse small
intestine is basal medium supplemented with EGF (50 ng/ml), Noggin
(100 ng/ml) and R-spondin-1 (1 μg/ml); andWnt-3A condition medium
was added to the small intestine organoid medium for culturing colon
organoids [23].
To assess the effect of Akt activation on DSS-induced cell death in
organoids, WT and DKO colon organoids grown in Matrigel were ﬁrst
recovered and resuspended in culture medium (DMEM + 10% FBS).
2% DSS or 2% DSS plus LY294002 (10 μM) dissolved in culture medium
were added to the organoid suspension and incubated for 4 h. At the
end of the treatment, organoidswere recovered via low speed centrifuga-
tion and analyzed using Western blot. The method of using short-term
in vitro DSS treatment to induce apoptosis in primary intestinal epithelial
cells and established epithelial cell lines has been used in a number of
previously published studies [21,24–26]. Disruption of barrier function
and increased secretion of pro-inﬂammatory cytokines from epithelialT) and PHLPP1/2 double knockout (DKO)mice by giving 2%DSS in drinkingwater for 7 days.
) and disease activity index (DAI) (B). The daily body weight after the administration of DSS
ed previously [20]. Data representmeans±SEM(n=12 forWTgroup including 5males and
O group by overall comparison of trend over time). Note that DKOmice of both genders were
WT andDKOmice treatedwith 2%DSS for 7 days and analyzed using hematoxylin and eosin
D) Histopathological analysis of DSS-induced colitis. Histological damage after DSS treatment
oup; *, P b 0.005 by the two-sample t-test). (E) Colon length ofWT and DKOmice exposed to
respectively; *, P b 0.0001 WT vs. DKO group by the two-sample t-test). (F) Analysis of the
O mice exposed to DSS for 7 days were analyzed using F4/80 staining. Scale bar for images
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cell death [24,25].
To assess TNFα-induced cell death in organoids, WT and DKO
organoids cultured in Matrigel for 4 days were treated with TNFα
(0 or 20 ng/ml) plus cycloheximide (2.5 μg/ml) for 3 h in the presence
of propidium iodide (PI, 3 μM) as previously described [27]. At the end
of treatment, cell death was visualized by incorporation of PI and
analyzed using a Nikon TE2000 inverted microscope. The intensity of
PI staining within each organoid was quantiﬁed and normalized to the
size of the organoid using NIS-Elements AR software. This is deﬁned as
the PI positive area and used to represent the level of cell death.
To determine LPS-induced PHLPP degradation in organoids, colon
organoids were embedded into Matrigel pre-mixed with LPS (50 μg/ml)
in organoid maintaining medium as described above and allowed to
grow for 24 h. During the last 3 h of LPS treatment, MG132 (20 μM)
was added into organoid maintaining medium. Subsequently, organoids
were recovered and lysed directly in lysis buffer.
2.6. Isolation and puriﬁcation of intestinal epithelial cells
Intestinal epithelial cells were isolated from the colon of control and
DSS-treated mice and puriﬁed using Percoll as described previously
[28]. Brieﬂy, mouse colon tissues were removed and cut into small
pieces. The colon pieces were incubated in DMEM/F12 supplemented
with 5% FBS and 2 mM DTT for 20 min at room temperature. After
removing the supernatant, colon pieces were incubated in DMEM/F12
supplemented with 5% FBS and 10 mM EDTA for 30 min at room
temperature. The dissociated intestine epithelial cells from colon were
further puriﬁed in 30% Percoll solution after centrifugation at 1300 rpm
for 20 min at room temperature. The epithelial cells were collected
from the top of Percoll layer and resuspended into cold PBS. The puriﬁed
epithelial cells were then recovered after centrifugation at 2000 rpm for
10 min. The viability of ﬁnal isolated IECs from both untreated and DSS-
treated mice was routinely around 80–90% as determined by FACS anal-
ysis using PI staining.
2.7. Western blot analysis
Human colon biopsies, puriﬁed colon epithelial cells, or cultured
organoids were harvested and lysed in Lysis Buffer (50 mM Na2HPO4,
1 mM sodium pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA,
1% Triton X-100, 1 mM DTT, 200 mM benzamidine, 40 mg ml−1
leupeptin, 200 mM PMSF) and the detergent-solubilized cell lysates
were obtained after centrifugation for 5 min at 16,000 g at 4 °C. Equal
amounts of cell lysates as determined by Bradford assays were resolved
by SDS-PAGE and subjected toWestern blot analysis. The density of ECL
signals was obtained and quantiﬁed using a FluoChem digital imaging
system (Alpha Innotech). The PHLPP1 antibody was purchased from
Proteintech and the PHLPP2 antibody was from Bethyl Laboratory. The
phospho-Akt (p-Akt for the Ser473 site), Akt and cleaved caspase 3
antibodies were obtained from Cell Signaling. The γ-tubulin antibody
was from Sigma-Aldrich. The PHLPP1, PHLPP2, p-Akt and total Akt
antibodies were used as 1:1000; the cleaved caspase 3 antibody
was used at 1:500 and the γ-tubulin antibody at 1:2000.
2.8. Real-time PCR
Total RNAwas isolated from puriﬁed colonic epithelial cells following
the DSS treatment using RNeasy kit (Qiagen). Equal amounts of RNA
were used as templates for the synthesis of cDNA using High Capacity
cDNA Reverse Transcription kit (Applied Biosystems). Real-time PCR
reaction was performed using PHLPP1- or PHLPP2-speciﬁc probes using
StepOne Real-Time PCR system (Applied Biosystems). All values were
normalized to the level of β-actin. The overall expression of β-actin
mRNA remained unchanged in different treatment groups as determined
by the Ct (threshold cycle) values for β-actin in each reaction.2.9. Human colonic specimens
Biopsy specimens were obtained from human patients undergoing
diagnostic or surveillance colonoscopies for UC or Crohn's disease,
or healthy individuals undergoing routine colon cancer surveillance.
Average 2–3 biopsies were collected from each individual and tissue
specimens were washed in PBS and further processed for Western
blot analysis. The biopsy specimens from patients with conﬁrmed UC
and Crohn's disease mainly consisted of inﬂamed tissues. No healthy
control or patients were on colitis treatment at the time of biopsy. The
Collection of all patient materials was approved by the University of
Kentucky's Ofﬁce for the Protection of Human Subjects and performed
at UK Good Samaritan Hospital.
2.10. Statistical analysis
Two-sample t-tests were used to compare statistical differences
between two groups in Western blot analyses. Values were expressed
as mean ± SEM. Comparison of colon length and histology score
between WT versus DKO groups was performed using the two-sample
t-test. The repeated measurements on disease index was analyzed
using linear mixed effects model to compare trend over time with con-
trast statement generated in themodel to compare slopebetweengroups.
The repeated body weight measurements were analyzed using linear
mixed effects model with a quadratic adjustment for the follow-up time
variable in the model and contrast generated to compare body weight
measurements over time between the two groups.
3. Results
3.1. DSS-induced colitis is suppressed in Phlpp1/2 DKO mice
We have previously shown that PHLPP-mediated dephosphorylation
and inactivation of Akt results in an increase in apoptosis and a decrease
in proliferation in colon cancer cells [13,14,22]. To determine if PHLPP
plays a role in regulating normal IEC cell survival in colitis, WT and
Phlpp1/2 DKO mice were subjected to DSS treatment. DSS-induced
acute colitis is associated with body weight loss, presence of grossly
bloody stool, crypt loss and damage of IECs [29]. After treatment with
2% DSS for 7 days, both WT and DKO mice lost weight. However, the
rate of weight loss was signiﬁcantly slower and the disease activity
index was signiﬁcantly lower in DKO mice compared to WT mice
(Figs. 1A–B). Histological analysis of H&E stained colon tissues revealed
less epithelial damage and disruption of crypt architecture in DKOmice
than in WT mice (Fig. 1C); and the overall histology score was
signiﬁcantly lower in DKO mice indicating less severe injury to the
epithelium (Fig. 1D). Moreover, DKO mice had relatively longer colon
length compared with WT mice (Fig. 1E). Consistent with less damage
to the colonic epithelium, macrophage inﬁltration was also reduced
in DSS-treated DKO mice as indicated by immunohistochemistry
staining of F4/80 (Fig. 1F). Taken together, our studies suggested
that PHLPP deﬁciency provides protection against DSS-induced
colitis in vivo.
3.2. Suppression of DSS-induced IEC apoptosis in Phlpp1/2 DKO mice
To determine the molecular mechanism underlying the protective
effect of PHLPP-loss onDSS-induced colitis, we determined the apoptotic
index in WT and DKOmice after DSS treatment. TUNEL staining of mice
colon showed that bothWT and DKOmice had very low basal apoptosis
rates before the DSS treatment. After the DSS treatment, the numbers of
apoptotic IECs were markedly increased inWTmice, whereas DKOmice
had signiﬁcantly lower degree of apoptosis compared to WT mice
(Figs. 2A–B). To further conﬁrm the effect of PHLPP-loss on de-
creased apoptosis, the expression of cleaved caspase-3, another
marker of apoptosis, was detected in isolated colon epithelial cells
2017Y.-A. Wen et al. / Biochimica et Biophysica Acta 1852 (2015) 2013–2023usingWestern blotting. Consistent with TUNEL staining results, the DSS
treatment induced apoptosis of IECs as indicated by increased cleaved
caspase-3 expression in both WT and DKO mice; however, the level of
cleaved caspase-3 was largely reduced in DKO mice (Fig. 2C, compare
lanes 3 and 4). Furthermore, the level of Akt phosphorylation was basally
increased inDKOmice consistentwith the phosphatase function of PHLPP
in inactivating Akt, and DSS-induced activation of Akt was further poten-
tiated in the absence of PHLPP expression (Fig. 2C). These results
indicated that loss of PHLPP expression inhibits IEC apoptosis and
activates Akt in DSS-induced colitis in vivo. Interestingly, we found that
knockout of single PHLPP isoform was not sufﬁcient to protect against
DSS-induced colitis in mice as the body weight loss was similar inFig. 2. PHLPP-loss inhibits DSS-induced IEC apoptosis in mice. (A) TUNEL staining of colon t
expressed as the number of TUNEL positive cells per 100 total cells counted. Colon tissues from
chosen areas. Data represent means ± SEM (n = 5; *, P b 0.0001 by two-sample t-tests). (C) W
and DKO mice. The relative levels of p-Akt and cleaved caspase-3 expression were quantiﬁed b
caspase-3 antibody to that of tubulin, respectively.Phlpp1–/−– and Phlpp2–/−– in comparisonwithWTmice (Supplementa-
ry Figs. S2A–B). In addition, knockout of either Phlpp1 or Phlpp2 isoform
resulted in an increase in the expression of the other PHLPP isoform in
mouse intestine tissues indicating potential compensation of the two
PHLPP isoforms. Indeed, although the basal phosphorylation of Akt was
increased in Phlpp1 or Phlpp2 deﬁcientmice, loss of single PHLPP isoform
was not sufﬁcient to potentiate Akt phosphorylation after DSS treatment
in either Phlpp1or Phlpp2deﬁcientmice (Supplementary Fig. S2C). Given
our previous ﬁndings that two PHLPP isoforms function similarly at
inactivating Akt, the results here suggested that loss of both PHLPP
isoform is required to defense against colitis-induced apoptosis of
intestinal epithelial cells.issues from DSS-treated WT and DKO mice. Scale bar, 100 μm. (B) Apoptosis index was
5 animals were analyzed in each group and cell counts were averaged from 4 randomly
estern blot analysis of colonic epithelial cells isolated from control and DSS-treated WT
y normalizing ECL signals of p-Akt (p-S473) antibody to that of total Akt and the cleaved
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through Akt activation
Since PHLPP-loss resulted in increased Akt activation and decreased
apoptosis of IECs in colitis (Fig. 2), we further tested the hypothesis that
activation of Akt is required for the protective effect seen in Phlpp1/2
DKO mice. To this end, we ﬁrst cultured colonic crypts isolated from
WT and DKO mice in 3D Matrigel. It has been shown that the organoid
model faithfully recapitulates in three dimensions the architecture of
the intestinal epithelium [23,30]. We found that the colonic crypts
organized into 3D acinar structures asmarked bymembrane expression
of β-catenin, and the actively proliferating cells were labeled with
5-ethynyl-2′-deoxyuridine (Edu) (Fig. 3A). The ability of colonic crypts
to form organoids and the morphology and proliferation rates of the
organoids were similar in WT and DKO mice (data not shown). This is
likely due to the fact that organoids derived from crypt stem cells
primarily rely on Wnt/ β-catenin signaling for proliferation and differ-
entiation [23]. To induce apoptosis, the organoids were treated with
2% DSS in the presence or absence of a PI3K inhibitor (LY294002) for
4 h. Consistent with the results obtained in vivo, apoptosis was inducedFig. 3. PHLPP-loss protects colonic organoids from DSS-induced apoptosis. Crypts isolated
fromWT and DKO colon tissues were seeded intoMatrigel and cultured for 4 days to obtain
organoids. (A) Phase contrast image of a representative colon organoid grown in 3DMatrigel
and immunoﬂuorescence staining of an organoid labeled with 5-ethynyl-2′-deoxyuridine
(EdU) (green), β-catenin (red) and DAPI (blue). Scale bar, 50 μm. (B) WT and DKO colon
organoids grown in Matrigel were ﬁrst recovered and resuspended in culture medium
then treated with 2% DSS or 2% DSS plus LY294002 (10 μM) for 4 h. Organoid lysates were
analyzed for the expression of PHLPP1, PHLPP2, and cleaved caspase-3 as well as the
phosphorylation status of Akt. The relative levels of p-Akt and cleaved caspase-3 expression
were quantiﬁed by normalizing ECL signals of p-Akt (p-S473) antibody to that of total Akt
and the cleaved caspase-3 antibody to that of tubulin, respectively.in both WT and DKO organoids treated with DSS as indicated by in-
creased expression of cleaved caspase-3 (Fig. 3B). However, DKO
organoids were more resistant to apoptosis compared with WT
organoids as indicated by the reduced cleaved caspase-3 expression
(Fig. 3B, compare lanes 3 and 4). Coincided with decreased apoptosis,
the phosphorylation of Akt was increased in DKO organoids suggesting
that activation of Akt likely protects IECs from DSS-induced apoptosis
(Fig. 3B). Since Crohn's disease can affect any part of the large intestine
and small intestine, we determined the effect of PHLPP-loss in organoids
derived from mouse small intestine as well. Similarly, DKO organoids of
small intestineweremore resistant toDSS-induced apoptosis, in that the
level of cleaved caspase-3 expression was largely reduced upon DSS
treatment when compared with WT organoids (Supplementary
Fig. S3). Moreover, combined treatment with the PI3K inhibitor
inactivated Akt in both WT and DKO organoids and the apoptotic effect
induced by DSS was further exacerbated as indicated by the increased
cleaved caspase-3 expression (Fig. 3B, lanes 5 and 6). The protective ef-
fect of PHLPP-loss against IEC apoptosis was largely attenuated in the
presence of the PI3K inhibitor, suggesting that the decreased apoptosis
seen in DKO organoids at least partially relies on increased activation
of Akt (Fig. 3B). Taken together, these results indicated that PHLPP is ca-
pable of regulatingDSS-induced apoptosis of IECs directly via controlling
Akt activity.
3.4. PHLPP-loss prevents TNFα-induced cell death in intestinal organoids
Wenext determine if PHLPP is involved in regulating theprogrammed
cell death in IECs induced by TNFα, a major cytokine that promotes intes-
tinal mucosal inﬂammation and damage in IBD. Numerous studies
have shown that TNFα expression is increased in IBD patients, and
TNFα-mediated signaling plays an important role in inducing apoptosis
in small intestine and colon tissues [31,32]. To examine TNFα-mediated
apoptosis, intestinal crypts were isolated from the intestine of WT and
DKO mice and cultured in 3D Matrigel for approximately 4 days to
allow the development of organoids (Fig. 4A). Short-term treatment
with TNFα induced marked apoptosis in WT organoids as indicated by
increased penetration of propidium iodide into the organoids; however,
this apoptosiswas signiﬁcantly inhibited inDKOorganoids (Figs. 4A–B).
Consistent with results obtained in DSS-treated organoids, TNFα-
treatment resulted in an increase in cleaved caspase-3 expression
indicating apoptosis induction (Fig. 4C). More importantly, PHLPP-loss
decreased the level of cleaved caspase-3 in TNFα treated organoids,
which coincided with increased Akt phosphorylation observed both
basally and in TNFα treated DKO organoids (Fig. 4C). Collectively,
these results demonstrated that loss of PHLPP expression protects IECs
from inﬂammatory factor TNFα-induced apoptosis by upregulating
Akt activity as well.
3.5. Inﬂammation promotes downregulation of PHLPP through proteasome-
mediated degradation
As shown above, we have found that PHLPP-loss plays a protective
role against DSS- and TNFα-induced apoptosis of IECs. To determine if
the expression of PHLPP is altered in colitis, we analyzed the expression
of PHLPP in IECs isolated from control and DSS-treated WT mice. The
results showed that the expression of both PHLPP isoforms was signiﬁ-
cantly decreased in mice treated with DSS, and as a consequence, the
level of Akt phosphorylation was increased (Figs. 5A–B). Similar de-
crease of PHLPP expression was observed in IL-10 knockout mice treat-
ed with piroxicam (Supplementary Fig. S4), another model of human
IBD, which is consistent with previous reports that elevated Akt phos-
phorylation is commonly associated with this colitis model as well
[16,33]. We next addressed the question whether the DSS treatment al-
ters the mRNA expression of PHLPP genes. Total RNAs were isolated
from colon epithelial cells of control and DSS-treated mice, and the ex-
pression of Phlpp1 and Phlpp2 mRNA was analyzed using real-time RT-
Fig. 4. PHLPP-loss prevents TNFα-induced cell death in small intestinal organoids. Crypts isolated fromWT and DKO small intestines were seeded intoMatrigel and cultured for 4 days to
obtain organoids. (A) TheWT and DKO organoidswere treatedwith TNFα (0 or 20 ng/ml) plus cycloheximide (2.5 μg/ml) for 3 h and stainedwith propidium iodide (PI). The appearance
of PI penetrating into unﬁxed cells indicates apoptosis. Images shown are merged bright ﬁeld and PI ﬂuorescence images. Scale bar, 100 μm. (B) The percentage of PI positive areas were
quantiﬁed using Nikon Element AR software. Data represent means± SEM (n= 5; *, P b 0.001 by two-sample t-tests). (C) TheWT and DKO organoids were treatedwith TNFα for 3 h as
described in (A). Organoid lysates were analyzed for the expression of PHLPP1, PHLPP2, and cleaved caspase-3 as well as the phosphorylation status of Akt. The relative levels of p-Akt and
cleaved caspase-3 expression were quantiﬁed by normalizing ECL signals of p-Akt (p-S473) antibody to that of total Akt and the cleaved caspase-3 antibody to that of tubulin, respectively.
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duced by the DSS treatment (Fig. 5C), suggesting that colitis-induced
PHLPP loss is likely controlled at the protein level.
To further determine the molecular mechanism of inﬂammation-
induced downregulation of PHLPP, we treated Caco2 cells with TNFα
or LPS to activate the inﬂammatory response. Similar as in DSS-treated
mice, both PHLPP isoforms were downregulated after 24 h of TNFα or
LPS treatment in Caco2 cells conﬁrming that PHLPP expression is
negatively regulated by inﬂammation (Figs. 6A–B). Furthermore,
treating cells with MG132, a proteasome inhibitor, partially prevented
the downregulation of PHLPP isoforms induced by TNFα or LPS (Figs.
6C–F). To conﬁrm the results obtained in Caco2 cells, we treated colonorganoids with LPS in the presence or absence of MG132. Similarly,
the expressionof both PHLPP isoformswas decreasedupon LPS treatment
and inhibition of proteasome activity reduced PHLPP downregulation
(Figs. 6G–H). Taken together, our results here demonstrated that
the proteasome-mediated degradation of PHLPP is upregulated under
inﬂammation-induced stress.
3.6. PHLPP is downregulated in human IBD patient samples
Furthermore, we determined the expression of PHLPP in human
colitis specimens and uninvolved colonic tissues from patients with
UC or Crohn's disease. As shown in Fig. 7, the expression of both
2020 Y.-A. Wen et al. / Biochimica et Biophysica Acta 1852 (2015) 2013–2023PHLPP1 and PHLPP2 isoform was signiﬁcantly decreased in colonic
biopsies collected from colitis tissues compared to normal controls.
As a consequence, the level of Akt phosphorylation was increased
in colitis tissues (Fig. 7A). Similar increase in Akt phosphorylation
in colitis has been reported in mouse models of IBD and in patients
with UC and active Crohn's disease [16,34].
In summary, we have identiﬁed PHLPP as a novel regulator of
inﬂammation-induced apoptosis of IECs in colitis. Our results supported
a model in which PHLPP expression in IECs is downregulated byFig. 5. PHLPP expression is downregulated in DSS-induced colitis in mice. (A) WT mice
were treatedwith 2%DSS for 4 days, and colonic epithelial cells were isolated from control
and DSS-treated mice. Cell lysates were analyzed for the expression of PHLPP1, PHLPP2,
and the phosphorylation level of Akt. (B) Western blots as shown in (A) were quantiﬁed
and the relative levels of PHLPPs were obtained by normalizing ECL signals of PHLPP1 or
PHLPP2 antibodies to that of tubulin. The expression level in untreated control mice was
set to 1. Data represent the mean ± SEM (n = 3, *P b 0.01 by two-sample t-tests).
(C) Total RNA was extracted from isolated colonic epithelial cells as described in (A).
Real-time RT-PCR analysis was performed using probes speciﬁc for the mouse PHLPP1
or PHLPP2 gene. Data represent the mean ± SD (n = 3).proteasome-mediated degradation upon exposure to inﬂammatory fac-
tors. Subsequently, the activity of Akt is upregulated to provide a feed-
back protection against apoptosis (Fig. 7C). However, persistent
activation of Akt signaling as the result of PHLPP downregulation
under inﬂammation may drive early tumorigenesis in colitis-associated
colon cancer.
4. Discussion
Although the underlying cause of IBD is inﬂammation, aberrant
apoptosis of IECs has been implicated as a major contributing factor in
the pathogenesis of IBD [35–37]. Previous studies have shown that
several known regulators of apoptosis, including p53, PUMA, and Bcl-2,
are involved in regulating colitis-induced apoptosis of IECs [32,36,38].
In this study, we found that PHLPP deﬁciency abrogates DSS-induced
acute colitis in mice by inhibiting IEC apoptosis. The resistance to
apoptosis in PHLPP DKO mice is likely mediated by upregulation of
Akt activity, as inhibition of PI3K/Akt attenuates the anti-apoptotic effect.
In addition, the expression of PHLPP is signiﬁcantly downregulated in
DSS-treated mice as well as in human IBD patient specimens, which
corresponds with elevated phosphorylation of Akt. Taken together, our
data identiﬁed PHLPP as a critical mediator of IEC apoptosis and a
novel regulator of IBD.
Previous studies have demonstrated that Akt activation downstream
of various inﬂammatory stimuli is associatedwith enhanced cell survival
and decreased epithelium damage in inﬂammation-induced mucosal
injury [16,39–41]. In addition, it has been suggested that maintaining
Akt activity is required for promoting injury repair of intestinal epithe-
lium. For example, colon-speciﬁc delivery of a probiotic-derived soluble
protein has been shown to prevent IEC apoptosis and DSS-induced
intestinal injury by activating EGFR and Akt signaling [42]. On the
other hand, inhibition of PI3K/Akt signaling blocks the protective func-
tion of ErbB4 in inhibiting cytokine-induced epithelial apoptosis [41].
Here, we showed that both PHLPP1 and PHLPP2 isoforms, key negative
regulators of Akt, could be readily downregulated in inﬂammation-
induced colitis. This decreased expression of PHLPP provides a novel
mechanism that allows rapid upregulation of Akt activity and subse-
quent protection against IEC apoptosis upon exposure to inﬂammatory
insults. The short-term downregulation of PHLPP likely plays a positive
role in protecting IECs from excessive death induced by acute colitis.
However, prolonged activation of PI3K/Akt signaling has been implicated
in the progression of chronic colitis to colitis-associated cancer [16]. Thus,
inﬂammation-induced PHLPP-loss is potentially an important risk factor
that predisposes IBD patients to colitis-associated cancer. Interestingly,
increasing evidence has suggested that inﬂammation plays a key role in
the initiation and progression of spontaneous colon cancers as well
[43]. The prevalence of inﬂammatory tumor microenvironment suggests
that inﬂammationmay be a general mechanism leading to PHLPP-loss in
cancer. It is intriguing that knockout of either PHLPP isoform by itself is
insufﬁcient to protect IECs from inﬂammation-induced apoptosis due to
the compensative effect of the two PHLPP isoforms. This is consistent
with previous ﬁndings that both PHLPP isoforms are commonly down-
regulated in colorectal cancer patients [12,22].
In determining themolecular mechanism of PHLPP downregulation,
we found that PHLPP expression is regulated at the post-translational
level in which the PHLPP proteins are degraded by the proteasome in
colitis. Similarly, we have shownpreviously that PHLPP is downregulated
under hypoxia via the proteasome-mediated degradation in colon cancer
cells [44]. A number of recent studies have implicated that tissue hypoxia,
particularly in mucosal surfaces involving epithelial cells, coincides with
acute and chronic intestinal inﬂammatory diseases [45–47]. Thus, it is
likely that inﬂammation-induced hypoxiamay lead to decreased expres-
sion of PHLPP by promoting proteasome-dependent PHLPP degradation,
and downregulation of PHLPP contributes to the pro-survival effect
activated by hypoxia. Although we have observed the effect of PHLPP-
loss on IECs directly, our results do not rule out the contribution from
Fig. 6. Inﬂammatory stimuli decrease PHLPP expression by promoting protein degradation. (A–B) Time course of TNFα- and LPS-induced PHLPP downregulation in Caco2 cells. Cells were
treated with TNFα (20 ng/ml) (A) or LPS (50 μg/ml) (B) for the indicated time, and cell lysates were prepared and analyzed for the expression of PHLPP1, PHLPP2 and tubulin usingWestern
blotting. The relative expression of PHLPP isoformswas quantiﬁed by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin, and this number for the untreated cells was
set to 1. (C–D) Caco2 cells were treated with TNFα for 24 h as described above. Proteasome inhibitor MG132 (20 μM) or DMSO was added to the cells for the last 3 h of the TNFα treatment.
(C) RepresentativeWestern blots showing the expression of PHLPP1, PHLPP2 and tubulin in cell lysates after different treatments. (D) The relative expression of PHLPP isoformswas quantiﬁed
by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin. The expression level in the control cellswas set to 1. Data represent themean±SEM (n=3). (E–F) Caco2 cells
were treatedwith LPS for 24 h as described above. Proteasome inhibitorMG132 (20 μM) or DMSOwas added to the cells for the last 3 h of the LPS treatment. (E) RepresentativeWestern blots
showing the expression of PHLPP1, PHLPP2 and tubulin in cell lysates after different treatments. (F) The relative expression of PHLPP isoforms was quantiﬁed by normalizing ECL signals
generated by the PHLPP antibodies to that of tubulin. The expression level in the control cells was set to 1. Data represent the mean ± SEM (n = 3). (G) Colon organoids of WT mice grown
in Matrigel were treated with LPS and MG132 as described above. Protein lysates were prepared from organoids after removing Matrigel. The expression of PHLPP1, PHLPP2 and tubulin
was analyzed using Western blotting. (H) The relative expression of PHLPP isoforms was quantiﬁed by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin. The
expression level under control condition was set to 1. Data represent the mean ± SEM (n = 3).
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Fig. 7. The expression of PHLPP isoforms is downregulated in IBD patient samples.
(A) Biopsy specimens from normal controls or IBD patients were lysed and analyzed for
the expression of PHLPP1, PHLPP2, and the phosphorylation level of Akt using Western
blotting. (B) Western blots as shown in (A) were quantiﬁed and the relative levels of
PHLPPs were obtained by normalizing ECL signals of PHLPP1 or PHLPP2 antibodies to
that of tubulin. The expression level in control samples was set to 1. Data represent the
mean ± SEM (n = 5, *P b 0.05 by two-sample t-tests). (C) Diagram showing the effect
of inﬂammation-induced downregulation of PHLPP on intestinal epithelial cell (IEC) apo-
ptosis. Our study demonstrates that PHLPP expression is downregulated by inﬂammatory
factors that are associatedwith IBD through increasedproteindegradation. As a consequence,
loss of PHLPP expression promotes the activation of Akt and protects IECs from
inﬂammation-induced apoptosis.
2022 Y.-A. Wen et al. / Biochimica et Biophysica Acta 1852 (2015) 2013–2023other cell types since the PHLPPDKOmice used in this study are systemic
knockout. It is possible that knockout of PHLPP expression in immune
cells may affect IEC apoptosis triggered by inﬂammation. More studies
are required to determine the involvement of PHLPP in different cell
types in the development of colitis.
Taken together, our study identiﬁed PHLPP as a novel regulator of
IEC apoptosis. Under acute colitis, PHLPP is downregulated as the result
of activation of inﬂammatory factors, and loss of PHLPP expression
inhibits IEC apoptosis by increasing Akt activity. It is attractive to consider
PHLPP inhibition as a potential anti-IBD strategy to protect against IEC
apoptosis. However, given the tumor suppressor role of PHLPP, prolonged
inhibition of PHLPP may contribute to increased risk of colon cancer in
IBD patients.
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